Cargando…

Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate

OBJECTIVES: Tumour necrosis factor inhibition plus methotrexate is believed to inhibit radiographic progression independent of inflammation. This analysis assessed whether these protective effects are exerted on bone (joint erosion; JE) and/or cartilage (joint space narrowing; JSN), and what the ind...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smolen, Josef S, van der Heijde, Désirée M, Keystone, Edward C, van Vollenhoven, Ronald F, Goldring, Mary B, Guérette, Benoît, Cifaldi, Mary A, Chen, Naijun, Liu, Shufang, Landewé, Robert B M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2013
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686261/ https://www.ncbi.nlm.nih.gov/pubmed/22915617 http://dx.doi.org/10.1136/annrheumdis-2012-201620

Ejemplares similares

Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
por: Keystone, Edward C, et al.
Publicado: (2017)

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate
por: Smolen, Josef S, et al.
Publicado: (2018)

Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis
por: Landewé, Robert, et al.
Publicado: (2015)

Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
por: Kavanaugh, Arthur, et al.
Publicado: (2013)

Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
por: Keystone, Edward, et al.
Publicado: (2014)

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
por: Smolen, J, et al.
Publicado: (2008)

Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
por: Smolen, Josef S., et al.
Publicado: (2015)

Inhibition of spinal bone formation in AS: 10 years after comparing adalimumab to OASIS
por: van der Heijde, Désirée, et al.
Publicado: (2019)

Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial
por: Strand, Vibeke, et al.
Publicado: (2011)

Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis
por: Keystone, Edward C, et al.
Publicado: (2018)

Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study
por: Smolen, Josef S, et al.
Publicado: (2014)

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
por: Combe, Bernard, et al.
Publicado: (2021)

Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy
por: Takeuchi, Tsutomu, et al.
Publicado: (2021)

Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
por: Sieper, Joachim, et al.
Publicado: (2013)

Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
por: Sieper, Joachim, et al.
Publicado: (2011)

Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts
por: Gherghe, Ana Maria, et al.
Publicado: (2015)

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
por: Stamm, Tanja Alexandra, et al.
Publicado: (2018)

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
por: Burmester, Gerd-Rűdiger, et al.
Publicado: (2015)

Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years
por: Rahman, Mahboob U, et al.
Publicado: (2011)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
por: Schiff, Michael, et al.
Publicado: (2014)

Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature
por: Visser, K, et al.
Publicado: (2008)

Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group
por: Halpern, M T, et al.
Publicado: (2008)

The Canadian Methotrexate and Etanercept Outcome Study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis
por: Pope, Janet E, et al.
Publicado: (2014)

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
por: Strand, Vibeke, et al.
Publicado: (2019)

Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research
por: Salliot, C, et al.
Publicado: (2008)

Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study
por: Haraoui, Boulos, et al.
Publicado: (2011)

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
por: Baranauskaite, Asta, et al.
Publicado: (2011)

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE
por: Tak, Paul P, et al.
Publicado: (2011)

Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years
por: van der Heijde, Désirée, et al.
Publicado: (2009)

Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate
por: Kavanaugh, A, et al.
Publicado: (2008)

Subtle changes in individual joints result in both positive and negative change scores in a patient: results from a clinical trial in patients with rheumatoid arthritis
por: Lukas, C, et al.
Publicado: (2008)

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
por: Genovese, Mark C, et al.
Publicado: (2019)

Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions
por: Van den Bosch, F, et al.
Publicado: (2010)

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
por: van der Heijde, D, et al.
Publicado: (2008)

Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre‐Specified Analysis of Two Phase III Trials
por: Combe, Bernard, et al.
Publicado: (2016)

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
por: Kerschbaumer, Andreas, et al.
Publicado: (2020)

Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial
por: Burmester, Gerd R, et al.
Publicado: (2017)

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
por: Emery, P, et al.
Publicado: (2017)

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_brvh2mh3su36hm3k4ngrro11vh